Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

OBJECTIVE: To describe a new systemic lupus erythematosus (SLE) Responder Index (SRI) based on the belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. METHODS: Data from a 449-patient randomized, double-blind, placebo-controlled study of 3 doses of belimumab (1...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Furie, Richard A., Petri, Michelle A., Wallace, Daniel J., Ginzler, Ellen M., Merrill, Joan T., Stohl, William, Chatham, W. Winn, Strand, Vibeke, Weinstein, Arthur, Chevrier, Marc R., Zhong, John, Freimuth, William W.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2748175/
https://ncbi.nlm.nih.gov/pubmed/19714615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.24698
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky